tbuckley/cabot-search huggingface dataset:
Hereditary Hemochromatosis
Authors: Victor Herbert
Journal: Annals of Internal Medicine (2001)

Letters18 December 2001Hereditary HemochromatosisVictor Herbert, MD, JDVictor Herbert, MD, JDMount Sinai-New York University Health System and Bronx Veterans Affairs Medical Center; Bronx, NY 10468Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-12-200112180-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Beutler and associates (1) again raise the question of whether the better predictor of phenotypic expression of hemochromatosis is the genotype or transferrin saturation. Perhaps a more important question is whether the better predictor is the genotype or ferritin saturation measured by quantitating atoms of iron per molecule of ferritin (2, 3). Ferritin, a circulating iron-storage protein, is in equilibrium with body iron stores. The shell of the ferritin protein molecule can store up to 4500 atoms of iron on its inner surface, unlike the transferrin molecule, a circulating iron-delivery protein, which can bind only 2 atoms ...References1. Beutler E, Felitti V, Gelbart T, Ho N. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med. 2000;133:329-37. [PMID: 10979877] LinkGoogle Scholar2. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P, Grady RW, et al . Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells. 1997;15:291-6. [PMID: 9253113] CrossrefMedlineGoogle Scholar3. Herbert V, Shaw S, Jayatilleke E. Vitamin C-driven free radical generation from iron. J Nutr. 1996;126:1213S-20S. [PMID: 8642459] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: Mount Sinai-New York University Health System and Bronx Veterans Affairs Medical Center; Bronx, NY 10468 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoThe Effect of HFE Genotypes on Measurements of Iron Overload in Patients Attending a Health Appraisal Clinic Ernest Beutler , Vincent Felitti , Terri Gelbart , and Ngoc Ho Hereditary Hemochromatosis Phillip B. Amidon and Rhonda D. Jankovich Metrics 18 December 2001Volume 135, Issue 12Page: 1091KeywordsFerritinHemochromatosisMembrane proteinsProteinsSerum ferritin levels ePublished: 18 December 2001 Issue Published: 18 December 2001 CopyrightCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
FDA approves lithotripter for kidney stone shattering
Authors: Charles Marnick
Journal: JAMA (1985)

The Food and Drug Administration has approved an ultrasonic kidney stone shattering device (<i>JAMA</i>[MEDICAL NEWS] 1983;249:2434-2435). This version of the device, technically called a lithotripter, was recommended for approval last May after extensive review of the clinical data by the FDA's advisory panel on gastroenterological and urological devices. The FDA commissioner acted on this advice just before the new year. This lithotripter has been used in treating some 10,000 patients with kidney stones in studies over the past five years in West Germany, as well as in several centers in the United States over the last year and a half. Currently, six centers in the United States have the device. The lithotripter was originally developed in West Germany by Dornier System of Friedrichshafen. The FDA has approved the lithotripter for treating stones formed in the renal calyx, pelvis, and upper third of the ureter. It is not suitable for
Identification of Blood Transfusion Reactions Occurring During Anesthesia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SATIRE
Authors: James Ransom
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de P. Sharma et al., pp. 400
Journal: Endoscopy (2011)

See also: Propofol sedation during endoscopy in patients with cirrhosis, and utility of psychometric tests and critical flicker frequency in assessment of recovery from sedationEndoscopy 2011; 43(05): 400-405DOI: 10.1055/s-0030-1256182
P17.36 * ENDOGENOUS NEURAL PRECURSOR CELLS INDUCE CELL DEATH OF HIGH-GRADE ASTROCYTOMAS AND HAVE A TROPISM TO TUMORS IN THE HUMAN BRAIN
Authors: R. Glass, K. Stock, J. Macas, H. Kettenmann, S. Momma, M. Synowitz
Journal: Neuro-Oncology (2014)

OBJECTIVE: Data from mouse models suggest that high-grade gliomas (HG-gliomas) origin from somatic mutant neural stem and precursor cells (NPCs). We found that endogenous NPCs also defend the brain against HG-gliomas. Here, we describe the signal transduction mechanism of NPC-mediated tumor suppression and present data on the tropism of endogenous NPCs to human HG-gliomas. METHODS: For our experiments, we used transgenic mouse models, human HG-glioma biopsies, molecular biology techniques (microarrays, real-time PCR, mass-spectrometry, array-CGH, fluorescence in situ hybridization), cell-culture (primary NPC- and glioma cultures of human and murine origin), immunohistochemistry and survival studies in orthotopic mouse tumour models. RESULTS: NPCs migrate from the subventricular zone to HG-gliomas, reduce glioma expansion and prolong survival by releasing a group of fatty acid ethanolamides that have agonistic activity on the vanilloid receptor (transient receptor potential vanilloid subfamily member-1; TRPV1). TRPV1 expression is much higher in HG-gliomas than in tumor-free brain and TRPV1 stimulation triggers tumor cell death. NPC-mediated tumor suppression can be mimicked in the adult brain by systemic administration of the synthetic vanilloids suggesting that TRPV1 agonists hold potential as new HGastrocytoma therapeutics. Furthermore, we analyzed the tumor-parenchyma interface of neurosurgical resections for the presence of NPCs and distinguished these physiological cells from the tumor mass. We observed that PSA-NCAM-positive NPCs, which are genetically distinct from the the tumor mass, accumulate at the border of high-grade gliomas and display a marker profile consistent with immature migratory neuronal progenitor cells. CONCLUSION: Overall, our data reveal a mechanism for NPC attraction CNS tumors and suggest that NPCs accumulate in human high-grade astrocytomas. In mouse models NPCs suppress HG-gliomas and the endogenous anti-tumorigenic factors can be used as pre-clinical HG-glioma therapeutics.
The Last Adam.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Investigation: A Manual for Practitioners and Students
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3133: Leukocyte telomere length, cancer incidence and all-cause mortality among Chinese adults: Singapore Chinese health study
Authors: Hamed Samavat, Hung N. Luu, Renwei Wang, Aizhen Jin, Woon-Puay Koh, Jian-Min Yuan
Journal: Cancer Research (2019)

Abstract Background: Telomeres play a key role in the chromosomal maintenance and stability. To date, very few studies have investigated the association between leukocyte telomere length with cancer incidence and all-cause mortality, particularly among Asian population. Methods: Relative telomere lengths in genomic DNA from peripheral blood samples were quantified using a validated quantitative real-time PCR among 26,540 middle-aged or older Chinese adults. Hazard ratios (HRs) and 95% confidence intervals (CIs) of incident cancer and deaths by quintiles of telomere length were calculated using the Cox proportional hazards regression method with adjustment for potential confounders. Results: During 13.2 years of follow-up, 4,353 individuals developed cancer and 2,660 participants died of cancer. Participants with the longest telomeres had significantly 16% higher risk of developing cancer compared to those with the shortest telomeres after controlling for established risk factors (95% CI: 1.06, 1.28; Ptrend= 0.0003). We found similar pattern of results for lung adenocarcinoma (HRQ5 vs. Q1=2.89; 95% CI: 1.95, 4.27), pancreatic cancer (HRQ5 vs. Q1=2.36; 95% CI: 1.29, 4.32), kidney cancer (HRQ5 vs. Q1=3.23; 95% CI: 1.47, 7.53), and genitourinary system cancers including kidney, renal pelvis, ureter, and bladder (HRQ5 vs. Q1=1.56; 95% CI: 1.02, 2.39). In contrast, longer telomeres were associated with lower risk of overall death (HRQ5 vs. Q1=0.93; 95% CI: 0.86, 1.00), and deaths due to ischemic heart disease (HRQ5 vs. Q1=0.85; 95% CI: 0.70, 1.02), respiratory disease (HRQ5 vs. Q1=0.76; 95% CI: 0.64, 0.91), non-cancer (HRQ5 vs. Q1=0.80; 95%: 0.73, 0.88) and other diseases (HRQ5 vs. Q1=0.77; 95% CI: 0.63, 0.94). Conclusion: The findings of this cohort study support the hypothesis that longer telomere length may be a risk factor for cancer and cancer-related deaths, but might have opposing impact on overall survival. Funding Sources: National Institutes of Health (NIH) (R01 CA144034 and UM1 CA182876); NIH/NCI T32CA186873; National Medical Research Council, Singapore (NMRC/CSA/0055/2013); NIH (P20CA210300). Citation Format: Hamed Samavat, Hung N. Luu, Renwei Wang, Aizhen Jin, Woon-Puay Koh, Jian-Min Yuan. Leukocyte telomere length, cancer incidence and all-cause mortality among Chinese adults: Singapore Chinese health study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3133.
Physicochemical and biochemical aspects of pharmacology
Authors: B. B. Brodie
Journal: JAMA (1967)

There are two facets to the problem of the biochemical and physical aspects of drug actions, the influence of drugs on the body and the influence of the body on drugs. In the past, pharmacology has emphasized the action of drugs on the living organism. But to be effective, a substance must have characteristics that allow it to reach its site of action in adequate concentration and to remain there for a suitable period of time. For this reason, we become concerned with the physical and biochemical factors that determine the duration of drug action. About 25 years ago, when I first became interested in the fate of drugs, I felt like the bat in Aesop's fable. Journals of pharmacology showed considerable reluctance in associating themselves with this "biochemical" topic, while biochemical journals refused these "drug" papers outright. But over the years pharmacology has broadened and these sort of studies
Lancet, London
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Software
Authors: Edward P. Hoffer
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heberden Society: Annual General Meeting and Oration
Authors: Daniel Mccarty, E Parke, V Fagan, G Chadwick, R Butler, M Stodell, V Zemelman, K Henry
Journal: Annals of the Rheumatic Diseases (1983)

Recent evidence has implicated the gastrointestinal tract as a source of antigen exposure in a variety of conditions, including certain rheumatic diseases.Putative mechanisms whereby antigen may reach the circulation from the gastrointestinal tract include local hypersensitivity reactions, IgA abnormality, or primary disturbances of gut permeability.In the present study we assessed gut permeability in patients with: rheumatoid arthritis (6), Sjogren's syndrome (4), coeliac disease (6), and coeliac disease + rheumatoid arthritis or Sjogren's syndrome (3), using polyethylene glycol polymers (average molecu- lar weight 600, 1500, and 4000), based on a 6-hour urine excretion profile using high performance liquid chromatographic analysis.These 4 patient groups were compared with an age and sex-matched group of normal controls.Gut permeability was abnormal in all coeliac patients.No abnormalities were found in the other patient groups studied.Gut permeability to macromolecules as assessed by this method is not abnormal in patients with rheumatoid arthritis and Sj6gren's syndrome.
From the Secretary of Health and Human Services
Authors: Louis W. Sullivan
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, February 1 to March 1, 1969
Journal: JNCI Journal of the National Cancer Institute (1969)

Journal Article Manuscripts Approved for JNCI, February 1 to March 1, 1969 Get access JNCI: Journal of the National Cancer Institute, Volume 42, Issue 4, April 1969, Pages 693–694, https://doi.org/10.1093/jnci/42.4.693-b Published: 01 April 1969
Publication of Updated Guide for Developing Policies for HIV-Infected Students and School Staff
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
3rd International Symposium on the Immunotherapy of the Rheumatic Diseases. 10-14 May 1995, Cyprus. Abstracts.
Authors: Gabriei Le H Kingsley, Jerry Lanchbury, Gabriel Panayi, Gabrielle Kingsley, L Adorini
Journal: Annals of the Rheumatic Diseases (1995)

Symposium on Immunotherapyas Tenidap (Dr Breedveld), appear to exert their effect via rather broad anticytokine profiles.No monoclonal anti- bodies against IL-1 have yet been used in clinical practice, though they are effective in animal models, but both a recombinant form of the natural IL-1 antagonist, IL-1 receptor antagonist (IL-Ira), and a recombinant soluble IL-1 receptor (Dr Moreland) have been used in RA.The former has undergone fairly extensive clinical trials, with modest success; its major handicap is likely to be the fact that high concentrations have to be maintained at all times to prevent signalling via the IL-1 pathway.The final presentation in this session (Dr C H Evans) reviewed the possibilities for gene therapy in arthritis using IL-ira as the antiarthritic gene.The gene has been delivered ex vivo to rabbit knees with beneficial effects on inflammation and cartilage destruction, and a human trial is about to begin.The last session of the meeting returned us to earth with something of a bump.Despite all the scientific advances resulting in the new therapies described above, we are still very bad at assessing disease activity and outcome in RA.In this session, Drs Scott, van Rijswijk and Emery, in reviewing clinical, radiological, biochemical, and genetic methods of assessment, aimed to reach a consensus about how new agents should be assessed-a task equal in difficulty and importance to any of the scientific discoveries alluded to earlier.The fact that it has become crucial to develop effective criteria for the assessment of RA shows that useful agents are, at last, becoming available.Immunotherapy has finally come of age.